Skip to main content
In stock|Targeted Therapy (Investigational)

Elenestinib

Oncology TypeHematologic
Drug Class / MechanismNext-Generation KIT D816V Inhibitor
No Image
Description

Elenestinib is classified as a Next-Generation KIT D816V Inhibitor, sourced for use within our Targeted Therapy (Investigational) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy (Investigational)
Oncology TypeHematologic

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3